Previous close | 10.10 |
Open | 10.10 |
Bid | 5.20 |
Ask | 14.90 |
Strike | 165.00 |
Expiry date | 2026-01-16 |
Day's range | 10.10 - 10.10 |
Contract range | N/A |
Volume | |
Open interest | 15 |
Biogen stock jumped Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?